While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change
Related Read: 14 Peptides Are About to Become Legal Again What This Means for Your Health What the science says about peptide stacking as a category 1) Combination trials are the exception, not the rule For many popular peptides, we have: mechanistic arguments small studies (sometimes in narrow contexts) preclinical work We rarely have: well-powered, long-term human trials on the combination hard outcomes (function, cardiometabolic endpoints, durability, safety) 2) Stacking amplifies the two biggest risks in this space Quality risk (variable purity, contamination, labeling issues) Physiology risk (more pathways affected, more unintended effects) 3) The GH/IGF-1 axis is where stacking gets most clinically delicate CJC-1295 has human data showing it raises GH/IGF-1

Ultimately, the question of whether retatrutide can be taken with sermorelin cannot be answered with a straightforward yes or no, given the current absence of interaction data and the unlicensed status of both agents in this context
Refrigeration at 2 to 8 degrees Celsius remains the recommended storage method after reconstitution
For a 200-pound person, it means 24 to 30 pounds